Remicade, Gilenya income boost Mitsubishi Tanabe's 2Q profit
This article was originally published in Scrip
Remicade (infliximab) contributed to Mitsubishi Tanabe Pharma's (MTP) results for the second quarter ended 30 September in more ways than one. Not only is the anti-TNF antibody the Japanese firm's top-selling product, a $117m arbitration settlement with licensor Janssen earlier this year also provided a healthy fillip to its net profit.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.